Status:

UNKNOWN

The RE-ENERGIZE Study: RandomizEd Trial of ENtERal Glutamine to minimIZE Thermal Injury

Lead Sponsor:

Daren K. Heyland

Collaborating Sponsors:

Canadian Institutes of Health Research (CIHR)

Conditions:

Burns

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to test the following hypotheses: 1. Enteral glutamine administration decreases in-hospital mortality in adult patients with severe thermal burn injuries. 2. Enteral glut...

Detailed Description

Burn injuries represent a public health problem worldwide, ranked fourth in all injuries and are among the leading cause of disability adjusted life years in low and middle-income countries. More than...

Eligibility Criteria

Inclusion

  • Deep 2nd and/or 3rd degree burns requiring grafting
  • Patient meets one of the following 4 criteria:
  • Patients 18 - 39 years of age with ≥ 20% TBSA\* burn
  • Patients 18 - 39 years of age with ≥ 15% TBSA\* burn and with inhalation injury
  • Patients 40 - 59 years of age with ≥ 15% TBSA\* burn
  • Patients ≥ 60 years of age ≥ 10% TBSA\* \*TBSA - Total Body Surface Area

Exclusion

  • \> 72 hrs from admission to ICU to time of consent.
  • Patients younger than 18 years of age.
  • a) Patients without known renal disease and renal dysfunction defined as a serum creatinine \>171 µmol/L or a urine output of less than 500 mL/last 24 hours (or 80 mL/last 4 hours if a 24 hour period of observation is not available).
  • b) Patients with acute on chronic renal failure (pre-dialysis) with an absolute increase of \>80 µmol/L from baseline or pre-admission creatinine or a urine output of \<500 mL/last 24 hours (or 80 mL/last 4 hours).
  • c) Patients with chronic renal failure on dialysis will be excluded.
  • Liver cirrhosis - Child-Pugh class C liver disease
  • Pregnant or lactating females.
  • Contra-indication for EN: intestinal occlusion or perforation, intra-abdominal injury.
  • Patients with injuries from high voltage electrical contact.
  • Patients who are moribund (not expected to survive the next 72 hours).
  • Patients with extreme body sizes: BMI \< 18 or \> 50
  • Enrollment in another industry sponsored ICU intervention study.
  • Received glutamine supplement for \> 24 hrs prior to randomization
  • Known allergy to maltodextrin, corn starch, corn, corn products or glutamine.

Key Trial Info

Start Date :

December 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2021

Estimated Enrollment :

1201 Patients enrolled

Trial Details

Trial ID

NCT00985205

Start Date

December 1 2010

End Date

December 1 2021

Last Update

December 30 2021

Active Locations (53)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 14 (53 locations)

1

University of South Alabama Medical Center

Mobile, Alabama, United States, 36609

2

Arizona Burn Center at Maricopa Medical Center

Phoenix, Arizona, United States, 85008

3

Southern California Regional Burn Ctr at LAC & USC Med. Ctr.

Los Angeles, California, United States, 90089-9235

4

Shriners Hospitals for Children Northern California

Sacramento, California, United States, 95817